Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

4.76
+0.14003.03%
Post-market: 4.760.00000.00%19:50 EDT
Volume:2.32M
Turnover:10.98M
Market Cap:597.14M
PE:-7.31
High:4.85
Open:4.62
Low:4.55
Close:4.62
52wk High:7.55
52wk Low:2.93
Shares:125.45M
Float Shares:115.00M
Volume Ratio:1.35
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6512
EPS(LYR):-0.7836
ROE:148.50%
ROA:-29.20%
PB:-10.55
PE(LYR):-6.07

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Aug 11

Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film

Dow Jones
·
Aug 10

Aquestive Therapeutics' Potential Allergy Film Shows Improvements in Human Factors Study

MT Newswires Live
·
Aug 10

Aquestive Reports Positive Human Factors, PK Results for Anaphylm Epinephrine Sublingual Film in Healthy Volunteers

Reuters
·
Aug 10

Aquestive Posts Anaphylm Study Presentation on Investor Website

Reuters
·
Aug 10

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (Dibutepinephrine) Sublingual Film

THOMSON REUTERS
·
Aug 10

Aquestive Therapeutics - Revised Anaphylm Packaging Reduces Median Pouch Opening Time to 3 Seconds

THOMSON REUTERS
·
Aug 10

Aquestive Therapeutics - Plans Anaphylm Nda Resubmission in Q3 2026

THOMSON REUTERS
·
Aug 10

Aquestive Therapeutics - Revised Instructions Reduce Incorrect Anaphylm Film Placement by over 80%

THOMSON REUTERS
·
Aug 10

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

GlobeNewswire
·
Jul 29

Aquestive Therapeutics CEO Daniel Barber Disposes of 25,000 Common Shares Worth $100,201.97

Reuters
·
Jul 18

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

GlobeNewswire
·
Jul 07

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders

TIPRANKS
·
Jun 27

Aquestive Therapeutics - Files Prospectus for Resale of up to 230,271 Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jun 27

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST), Revolution Medicines (RVMD) and Bolt Biotherapeutics (BOLT)

TIPRANKS
·
Jun 25

Aquestive Therapeutics Director Julie Krop Disposes of 25,000 Common Shares for $125,392.5

Reuters
·
Jun 24

Aquestive Therapeutics CEO Daniel Barber sells 25,000 shares for $104,010

Reuters
·
Jun 17

Aquestive Therapeutics holds annual shareholder meeting

Reuters
·
Jun 11

Aquestive CEO Daniel Barber disposes of 8,257 shares worth $35,406.44

Reuters
·
May 19